Content
05/06/2025
S. San Francisco, CA USA
NewLimit
completed $130 million Series B Round funding. Investors include
Kleiner Perkins Caufield and Byers (lead), NFDG, Khosla Ventures, Human Capital, Valor Equity Partners, Dimension, Founders Fund.
About
NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.
Startup
Sector:
Biotech
Healthcare
Life Science
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
